EBRO 2017

The EXPERT-C trial – Design

CAPOX

CRT with Capecitabine

Neoadjuvant CAPOX x 4

Adjuvant CAPOX x 4

TME

R*

CRT with Capecitabine & Cetuximab

Adjuvant CAPOX-C x 4

Neoadjuvant CAPOX-C x 4

TME

CAPOX + CETUXIMAB

*Patients recruited from 15 European Centres 2005-2008

Key inclusion criteria: • Tumours within 1mm of mesorectal fascia • Tumours extending  5mm into peri-rectal fat • T4 tumours • Presence of extramural vascular invasion • T3 tumours at/below levators

Endpoints • Primary endpoint:

CR in KRAS/BRAF WT patients

• Secondary endpoints:

RR, PFS, OS, safety and QoL

Dewdney, J Clin Oncol 2012